Literature DB >> 22223404

Correlation of the vesicular acetylcholine transporter densities in the striata to the clinical abilities of women with Rett syndrome.

James Robert Brašić1, Genila Bibat, Anil Kumar, Yun Zhou, John Hilton, Marybeth E Yablonski, Ahmet Semih Dogan, Maria Rita Guevara, Massoud Stephane, Michael Johnston, Dean Foster Wong, Sakkubai Naidu.   

Abstract

Rett syndrome (RTT) is a pan class="Disease">neurodevelopmental disability characterized by mutations in the X-linked methyl-CpG-binding protein 2 located at the Xq28 region. The severity is modified in part by X chromosomal inactivation resulting in wide clinical variability. We hypothesized that the ability to perform the activities of daily living (ADL) is correlated with the density of vesicular acetylcholine transporters in the striata of women with RTT. The density of the vesicular acetylcholine transporters in the living human brain can be estimated by single-photon emission-computed tomography (SPECT) after the administration of (-)-5-[¹²³I]iodobenzovesamicol ([¹²³I]IBVM). Twenty-four hours following the intravenous injection of ∼333 MBq (9 mCi) [¹²³ I]IBVM, four women with RTT and nine healthy adult volunteer control participants underwent SPECT brain scans for 60 min. The Vesicular Acetylcholine Transporter Binding Site Index (Kuhl et al., 1994), a measurement of the density of vesicular acetylcholine transporters, was estimated in the striatum and the reference structure, the cerebellum. The women with RTT were assessed for certain ADL. Although the striatal Vesicular Acetylcholine Transporter Binding Site Index was not significantly lower in RTT (5.2 ± 0.9) than in healthy adults (5.7 ± 1.6), RTT striatal Vesicular Acetylcholine Transporter Binding Site Indices and ADL scores were linearly associated (ADL = 0.89*(Vesicular Acetylcholine Transporter Binding Site Index) + 4.5; R² = 0.93; P < 0.01), suggesting a correlation between the ability to perform ADL and the density of vesicular acetylcholine transporters in the striata of women with RTT. [¹²³I]IBVM is a promising tool to characterize the pathophysiological mechanisms of RTT and other neurodevelopmental disabilities.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223404      PMCID: PMC3480211          DOI: 10.1002/syn.21515

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  61 in total

1.  Rett syndrome: North American database.

Authors:  Alan K Percy; Jane B Lane; Jerry Childers; Steve Skinner; Fran Annese; Judy Barrish; Erwin Caeg; Daniel G Glaze; Patrick MacLeod
Journal:  J Child Neurol       Date:  2007-12       Impact factor: 1.987

2.  (E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter.

Authors:  Patrick Emond; Sylvie Mavel; Yolanda Zea-Ponce; Michael Kassiou; Lucette Garreau; Sylvie Bodard; Marie-Laure Drossard; Sylvie Chalon; Denis Guilloteau
Journal:  Nucl Med Biol       Date:  2007-09-19       Impact factor: 2.408

3.  Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Authors:  James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong
Journal:  Synapse       Date:  2009-04       Impact factor: 2.562

4.  White matter impairment in Rett syndrome: diffusion tensor imaging study with clinical correlations.

Authors:  A Mahmood; G Bibat; A-L Zhan; I Izbudak; L Farage; A Horska; S Mori; S Naidu
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-15       Impact factor: 3.825

5.  Selective cerebral volume reduction in Rett syndrome: a multiple-approach MR imaging study.

Authors:  J C Carter; D C Lanham; D Pham; G Bibat; S Naidu; W E Kaufmann
Journal:  AJNR Am J Neuroradiol       Date:  2007-12-07       Impact factor: 3.825

6.  Investigating genotype-phenotype relationships in Rett syndrome using an international data set.

Authors:  A Bebbington; A Anderson; D Ravine; S Fyfe; M Pineda; N de Klerk; B Ben-Zeev; N Yatawara; A Percy; W E Kaufmann; H Leonard
Journal:  Neurology       Date:  2008-03-11       Impact factor: 9.910

7.  Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome.

Authors:  J L Neul; P Fang; J Barrish; J Lane; E B Caeg; E O Smith; H Zoghbi; A Percy; D G Glaze
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

8.  Comparison of noninvasive quantification methods of in vivo vesicular acetylcholine transporter using [123I]-IBVM SPECT imaging.

Authors:  O Barret; J Mazère; J Seibyl; M Allard
Journal:  J Cereb Blood Flow Metab       Date:  2008-05-28       Impact factor: 6.200

9.  Updating the profile of C-terminal MECP2 deletions in Rett syndrome.

Authors:  A Bebbington; A Percy; J Christodoulou; D Ravine; G Ho; P Jacoby; A Anderson; M Pineda; B Ben Zeev; N Bahi-Buisson; E Smeets; H Leonard
Journal:  J Med Genet       Date:  2009-11-12       Impact factor: 6.318

10.  Brain metabolism in Rett syndrome: age, clinical, and genotype correlations.

Authors:  Alena Horská; Luciano Farage; Genila Bibat; Lídia M Nagae; Walter E Kaufmann; Peter B Barker; SakkuBai Naidu
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

View more
  8 in total

1.  Cholinergic systems are essential for late-stage maturation and refinement of motor cortical circuits.

Authors:  Dhakshin S Ramanathan; James M Conner; Arjun A Anilkumar; Mark H Tuszynski
Journal:  J Neurophysiol       Date:  2014-12-10       Impact factor: 2.714

Review 2.  Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits.

Authors:  Samuel S Pappas; Daniel K Leventhal; Roger L Albin; William T Dauer
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

3.  GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Authors:  Jay S Schneider; Franca Cambi; Stephen M Gollomp; Hiroto Kuwabara; James R Brašić; Benjamin Leiby; Stephanie Sendek; Dean F Wong
Journal:  J Neurol Sci       Date:  2015-06-16       Impact factor: 3.181

4.  Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome.

Authors:  James R Brašić; Ayon Nandi; David S Russell; Danna Jennings; Olivier Barret; Anil Mathur; Keith Slifer; Thomas Sedlak; Samuel D Martin; Zabecca Brinson; Pankhuri Vyas; John P Seibyl; Elizabeth M Berry-Kravis; Dean F Wong; Dejan B Budimirovic
Journal:  Brain Sci       Date:  2020-11-24

Review 5.  Excitation and Inhibition Imbalance in Rett Syndrome.

Authors:  Wei Li
Journal:  Front Neurosci       Date:  2022-02-18       Impact factor: 4.677

6.  Mecp2 Deletion from Cholinergic Neurons Selectively Impairs Recognition Memory and Disrupts Cholinergic Modulation of the Perirhinal Cortex.

Authors:  Elizabeth C Ballinger; Christian P Schaaf; Akash J Patel; Antonia de Maio; Huifang Tao; David A Talmage; Huda Y Zoghbi; Lorna W Role
Journal:  eNeuro       Date:  2019-11-01

7.  Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study.

Authors:  James Robert Brašić; Ayon Nandi; David S Russell; Danna Jennings; Olivier Barret; Samuel D Martin; Keith Slifer; Thomas Sedlak; John P Seibyl; Dean F Wong; Dejan B Budimirovic
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

8.  Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study.

Authors:  James Robert Brašić; Jack Alexander Goodman; Ayon Nandi; David S Russell; Danna Jennings; Olivier Barret; Samuel D Martin; Keith Slifer; Thomas Sedlak; Anil Kumar Mathur; John P Seibyl; Elizabeth M Berry-Kravis; Dean F Wong; Dejan B Budimirovic
Journal:  Brain Sci       Date:  2022-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.